1. Home
  2. KZR vs GBIO Comparison

KZR vs GBIO Comparison

Compare KZR & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kezar Life Sciences Inc.

KZR

Kezar Life Sciences Inc.

HOLD

Current Price

$6.25

Market Cap

29.7M

Sector

Health Care

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.22

Market Cap

35.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KZR
GBIO
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.7M
35.4M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
KZR
GBIO
Price
$6.25
$5.22
Analyst Decision
Hold
Buy
Analyst Count
4
4
Target Price
$6.00
$10.67
AVG Volume (30 Days)
35.4K
57.4K
Earning Date
11-12-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.53
$3.00
52 Week High
$7.27
$14.20

Technical Indicators

Market Signals
Indicator
KZR
GBIO
Relative Strength Index (RSI) 64.26 47.21
Support Level $6.05 $5.14
Resistance Level $6.29 $5.38
Average True Range (ATR) 0.14 0.25
MACD -0.05 0.02
Stochastic Oscillator 76.00 49.35

Price Performance

Historical Comparison
KZR
GBIO

About KZR Kezar Life Sciences Inc.

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: